Long-Term Outcomes of Patients With Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score
aHCM constituted 6.8% of our overall HCM cohort with a composite event rate of 2.8%/year. The aHCM risk score provided good discrimination in predicting the composite primary endpoint, with a higher score associated with a higher rate of events.
Authors
- Zoran Popović (ORCID: https://orcid.org/0000-0001-5692-2299)
- Adel Hajj-Ali
- Emmanuel Akintoye (ORCID: https://orcid.org/0000-0002-1264-3383)
- Andrew Gaballa (ORCID: https://orcid.org/0009-0008-8619-3400)
- Milind Y. Desai (ORCID: https://orcid.org/0000-0003-0010-9797)
- Susan Ospina (ORCID: https://orcid.org/0009-0004-7175-6582)
- Bo Xu (ORCID: https://orcid.org/0000-0002-2985-7468)
- Nicholas G. Smedira (ORCID: https://orcid.org/0000-0002-4963-8588)
- Maran Thamilarasan
- Jay Ramchand (ORCID: https://orcid.org/0000-0001-8591-1986)
- Shada Jadam (ORCID: https://orcid.org/0009-0005-6175-4775)
Institutions
- Cleveland Clinic (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.jacadv.2024.101235
- Citations
- 10
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.02